Kryger Capital LLC Purchases New Stake in Kenvue Inc. $KVUE

Kryger Capital LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 5,211,114 shares of the company’s stock, valued at approximately $89,840,000. Kenvue accounts for 6.4% of Kryger Capital LLC’s portfolio, making the stock its 6th largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new position in shares of Kenvue in the 4th quarter valued at about $26,000. Physician Wealth Advisors Inc. raised its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. MV Capital Management Inc. bought a new stake in shares of Kenvue during the fourth quarter worth approximately $28,000. Reflection Asset Management acquired a new position in Kenvue in the fourth quarter valued at approximately $32,000. Finally, SBI Securities Co. Ltd. lifted its holdings in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares during the period. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.59% of the company’s stock.

Kenvue Stock Up 1.9%

Shares of Kenvue stock opened at $19.25 on Friday. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The business has a 50-day moving average of $18.38 and a two-hundred day moving average of $17.92. The company has a market capitalization of $36.97 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 1.43 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the previous year, the business posted $0.24 EPS. Kenvue’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.3%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on KVUE shares. Citigroup reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Wall Street Zen raised Kenvue to a “buy” rating in a research note on Sunday, July 12th. Barclays raised their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.